Uwe Zeymer REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida UWE ZEYMER, Herzzentrum Ludwigshafen, Germany The gl

Uwe ZeymerREFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, FloridaUWE ZEYMER, Herzzentrum Ludwigshafen, GermanyThe glycoprotein 2B 3A antagonist eptifibatide has performed as well as standard abciximab therapy in patients receiving primary angioplasty for acute myocardial infarction. So according toUwe Zeymerwho presented findings on this it can be used in this setting just as it is already being used in elective PCI. Sarah Maxwell interviewed Dr Zeymer at the Orlando conference.
Related Episodes

LDL-How Low?
Terje Pedersen Terje Pedersen, Ulleval University, Oslo Eugene Braunwald, Harvard University, Boston Lowering LDL Cholesterol intensively as a means of treating aortic stenosis was found to have no be

Bivalirudin For Angioplasty: Expensive Heparin?
Tony Gershlick Tony Gershlick, University of Leicester Adnan Kastrati, Deutsches Herzzentrum, Munich Using bivalirudin instead of heparin during angioplasty wasn’t any better for preventing deat

Remove Thrombus Before Primary Angioplasty!
Felix Zijlstra Felix Zijlstra, University Medical Center Groningen, The Netherlands Thrombus aspiration before percutaneous coronary intervention for acute myocardial infarction has multiple benefits,
